← Back to Search

Vasodilator

Blood Flow Improvement Drugs + Supplements for Heart Failure (MPMA Trial)

Phase 2
Recruiting
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
a. Mitral early (E)/mitral septal tissue annular (e') velocity ratio > 8, in the context of a septal e' velocity <=7, in addition to one of the following: i. Large left atrium (LA volume index > 34 mL/m2) ii. Chronic loop diuretic use for control of symptoms iii. Elevated natriuretic peptides within the past year (e.g. NTproBNP > 125 pg/mL in sinus rhythm or > 375 pg/mL if in atrial fibrillation) b. Mitral E/e' ratio > 14 at rest or during exercise c. Elevated invasively-determined filling pressures previously (resting left ventricular end-diastolic pressure >= 16 mm Hg or pulmonary capillary wedge pressure >= 15 mmHg; or PCWP/LVEDP >= 25 mmHg with exercise) d. Prior episode of acute heart failure requiring IV diuretics
Stable medical therapy for at least 1 month
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 6
Awards & highlights

MPMA Trial Summary

This trial will test whether drugs that improve blood flow, with or without supplements that may improve mitochondrial function, can improve exercise endurance and skeletal muscle function in people with HFpEF.

Who is the study for?
This trial is for adults with Heart Failure with Preserved Ejection Fraction (HFpEF), who have been on stable heart medication for at least a month. They should have certain signs of heart stress, like specific ratios in their echocardiogram or history of acute heart failure. Excluded are those under 18, pregnant women, people with severe other diseases or conditions that could interfere with the study, and those taking conflicting medications.Check my eligibility
What is being tested?
The study tests if Potassium Nitrate alone or combined with Propionyl-L-Carnitine and Nicotinamide Riboside can improve exercise endurance and muscle function in HFpEF patients. It compares these treatments to Potassium Chloride to see which is better at increasing blood flow and enhancing mitochondrial function.See study design
What are the potential side effects?
Possible side effects may include changes in blood pressure, dizziness upon standing due to orthostatic hypotension, potential impact on liver enzymes (ALT/AST levels), alterations in kidney function as measured by eGFR rates, and increased methemoglobin levels which affect oxygen delivery.

MPMA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your heart has certain measurements and pressures that show it may not be working properly, or you've had a previous episode of acute heart failure requiring intravenous diuretics.
Select...
My current medication has been the same for at least 1 month.
Select...
My heart pumps blood effectively.
Select...
I have moderate heart condition symptoms.

MPMA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Submaximal Exercise Endurance
Secondary outcome measures
Kansas City Cardiomyopathy Questionnaire Overall Summary Score
Peak VO2
Skeletal muscle structure
+4 more
Other outcome measures
Change in Skeletal Muscle Oxidative Capacity

MPMA Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Potassium NitrateActive Control1 Intervention
Potassium Nitrate (KNO3) 6 mmol three times daily
Group II: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide RibosideActive Control1 Intervention
Potassium Nitrate (KNO3) 6 mmol three times daily + Propionyl-L-Carnitine (PLC) 1000 mg twice daily + Nicotinamide Riboside (NR) 300 mg three times daily
Group III: Potassium ChloridePlacebo Group1 Intervention
Potassium Chloride (KCl) 6 mmol three times daily

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,879,827 Total Patients Enrolled
42 Trials studying Heart Failure
7,461 Patients Enrolled for Heart Failure

Media Library

Potassium Nitrate (Vasodilator) Clinical Trial Eligibility Overview. Trial Name: NCT04913805 — Phase 2
Heart Failure Clinical Trial 2023: Potassium Nitrate Highlights & Side Effects. Trial Name: NCT04913805 — Phase 2
Heart Failure Research Study Groups: Potassium Nitrate, Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside, Potassium Chloride
Potassium Nitrate (Vasodilator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04913805 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Food and Drug Administration granted authorization for Potassium Nitrate?

"Potassium Nitrate has been tested and garnered a score of 2 on the safety scale; while there is some data supporting its security, it has yet to be proven effective in clinical trials."

Answered by AI

What is the maximum number of participants included in this clinical investigation?

"Affirmative. The information hosted on clinicaltrials.gov reveals that this investigation is still actively recruiting, which began October 11th 2021 and was most recently modified April 27th 2022. At the moment, 53 participants are necessary for 1 centre involved in the trial."

Answered by AI

Does this trial restrict participants to those over 80 years of age?

"The age limits for this medical study are 18 and above, with an upper limit of 85 years old."

Answered by AI

Could I potentially be enrolled in this research program?

"A total of 53 individuals aged 18-85 suffering from heart failure with preserved ejection fraction (hfpef) may join this trial. Beyond that, they must have taken a stable medical therapy for at least one month and display NYHA Class II-III symptoms."

Answered by AI

In what medical contexts is Potassium Nitrate commonly administered?

"Potassium Nitrate is a helpful tool in managing congestive heart failure (CHF), increasing sensitivity, looking after teeth, and aiding with lower extremity issues."

Answered by AI

Could you provide information on preceding research involving Potassium Nitrate?

"Currently, 18 clinical research trials are underway on the efficacy of Potassium Nitrate. Of those active studies, 2 have advanced to Phase 3. Philadelphia serves as a major hub for these investigations with 22 locations conducting experiments into this medication's effects."

Answered by AI

Is enrollment still available for this experiment?

"Indeed, the data hosted on clinicaltrials.gov indicates that this medical study is actively recruiting patients. Initially posted on October 11th 2021, it has been recently updated as of April 27th 2022 and requires 53 participants from one site."

Answered by AI
~22 spots leftby Jan 2026